India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 1.04 trillion. The enterprise value is 1.08 trillion.
| Market Cap | 1.04T |
| Enterprise Value | 1.08T |
Important Dates
The next confirmed earnings date is Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mankind Pharma has 413.00 million shares outstanding. The number of shares has increased by 2.13% in one year.
| Current Share Class | 413.00M |
| Shares Outstanding | 413.00M |
| Shares Change (YoY) | +2.13% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 57.69% |
| Owned by Institutions (%) | 20.89% |
| Float | 112.99M |
Valuation Ratios
The trailing PE ratio is 54.17 and the forward PE ratio is 43.84. Mankind Pharma's PEG ratio is 2.33.
| PE Ratio | 54.17 |
| Forward PE | 43.84 |
| PS Ratio | 7.25 |
| PB Ratio | 6.25 |
| P/TBV Ratio | 621.53 |
| P/FCF Ratio | 41.50 |
| P/OCF Ratio | 33.17 |
| PEG Ratio | 2.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.41, with an EV/FCF ratio of 43.25.
| EV / Earnings | 56.41 |
| EV / Sales | 7.56 |
| EV / EBITDA | 29.41 |
| EV / EBIT | 38.12 |
| EV / FCF | 43.25 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.07 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 2.53 |
| Interest Coverage | 4.45 |
Financial Efficiency
Return on equity (ROE) is 12.45% and return on invested capital (ROIC) is 11.41%.
| Return on Equity (ROE) | 12.45% |
| Return on Assets (ROA) | 6.31% |
| Return on Invested Capital (ROIC) | 11.41% |
| Return on Capital Employed (ROCE) | 13.07% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | 6.98M |
| Profits Per Employee | 935,372 |
| Employee Count | 20,451 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.01 |
Taxes
In the past 12 months, Mankind Pharma has paid 3.95 billion in taxes.
| Income Tax | 3.95B |
| Effective Tax Rate | 16.92% |
Stock Price Statistics
The stock price has decreased by -3.35% in the last 52 weeks. The beta is 0.45, so Mankind Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -3.35% |
| 50-Day Moving Average | 2,464.37 |
| 200-Day Moving Average | 2,274.57 |
| Relative Strength Index (RSI) | 50.58 |
| Average Volume (20 Days) | 372,650 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 142.78 billion and earned 19.13 billion in profits. Earnings per share was 46.28.
| Revenue | 142.78B |
| Gross Profit | 100.13B |
| Operating Income | 28.19B |
| Pretax Income | 23.33B |
| Net Income | 19.13B |
| EBITDA | 36.30B |
| EBIT | 28.19B |
| Earnings Per Share (EPS) | 46.28 |
Balance Sheet
The company has 22.08 billion in cash and 63.12 billion in debt, with a net cash position of -41.04 billion or -99.37 per share.
| Cash & Cash Equivalents | 22.08B |
| Total Debt | 63.12B |
| Net Cash | -41.04B |
| Net Cash Per Share | -99.37 |
| Equity (Book Value) | 165.61B |
| Book Value Per Share | 394.85 |
| Working Capital | 4.47B |
Cash Flow
In the last 12 months, operating cash flow was 31.21 billion and capital expenditures -6.26 billion, giving a free cash flow of 24.95 billion.
| Operating Cash Flow | 31.21B |
| Capital Expenditures | -6.26B |
| Depreciation & Amortization | 8.11B |
| Net Borrowing | -22.64B |
| Free Cash Flow | 24.95B |
| FCF Per Share | 60.42 |
Margins
Gross margin is 70.13%, with operating and profit margins of 19.74% and 13.40%.
| Gross Margin | 70.13% |
| Operating Margin | 19.74% |
| Pretax Margin | 16.34% |
| Profit Margin | 13.40% |
| EBITDA Margin | 25.42% |
| EBIT Margin | 19.74% |
| FCF Margin | 17.48% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.16% |
| Buyback Yield | -2.13% |
| Shareholder Yield | -2.05% |
| Earnings Yield | 1.85% |
| FCF Yield | 2.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Mankind Pharma is 2,667.68, which is 6.20% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,667.68 |
| Price Target Difference | 6.20% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 11.38% |
| EPS Growth Forecast (3Y) | 16.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mankind Pharma has an Altman Z-Score of 6.62 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.62 |
| Piotroski F-Score | 6 |